MOLECULAR GENETICS

TMS (Tandem Mass Spectrometry) and other biochemical/enzymatic/molecular assays
This comprehensive newborn screening panel utilizes a combination of advanced analytical techniques to detect a wide array of congenital, genetic, and metabolic disorders. This panel combines the robust capabilities of TMS with other specific assays for an even broader screening scope. * TMS (Tandem Mass Spectrometry): This is the primary method for screening for 52 Inborn Errors of Metabolism (IEMs) from a dried blood spot (DBS). TMS is highly sensitive and specific for simultaneously measuring abnormal levels of various metabolites (amino acids, acylcarnitines, succinylacetones, etc.) in a single run. * 52 Conditions by TMS: This extensively covers a broad spectrum of disorders, including: * Amino Acid Disorders (Aminoacidopathies): Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Tyrosinemia (Types I, II, III), Citrullinemia (Type I, II), Argininemia, Argininosuccinic Acidemia, etc. * Organic Acid Disorders (Organic Acidemias): Propionic Acidemia, Methylmalonic Acidemia, Isovaleric Acidemia, Glutaric Acidemia Type I, 3-Methylcrotonyl-CoA Carboxylase Deficiency, Multiple Carboxylase Deficiency, etc. * Fatty Acid Oxidation Disorders: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD), Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCADD), Carnitine Uptake Defect, Carnitine Palmitoyl Transferase Deficiencies, etc. * Other Biochemical/Enzymatic/Molecular Assays (for the 11 Conditions): These conditions are typically screened using established methods distinct from TMS, or are key conditions that might overlap with TMS but are also typically listed separately in expanded panels. While the exact list of "11 conditions" can vary slightly by laboratory or regional guidelines, it typically includes core conditions and additional significant disorders: * Congenital Hypothyroidism (CH): Detected by elevated Thyroid Stimulating Hormone (TSH) and/or low T4 levels (often by Fluoroimmunoassay - FIA). * Congenital Adrenal Hyperplasia (CAH): Detected by elevated 17-hydroxyprogesterone (17-OHP) (often by FIA). * G6PD Deficiency (Glucose-6-Phosphate Dehydrogenase Deficiency): Detected by measuring G6PD enzyme activity. * Galactosemia: Detected by elevated total galactose or galactose-1-phosphate, or by measuring Galactose-1-Phosphate Uridyltransferase (GALT) enzyme activity. * Biotinidase Deficiency (BTD): Detected by measuring biotinidase enzyme activity. * Cystic Fibrosis (CF): Often screened by immunoreactive trypsinogen (IRT), with reflex DNA testing for common CFTR gene mutations if IRT is elevated. * Hemoglobinopathies (e.g., Sickle Cell Disease, Beta Thalassemia): Screened using methods like HPLC (High-Performance Liquid Chromatography) or IEF (Isoelectric Focusing) to identify abnormal hemoglobin variants. * Severe Combined Immunodeficiency (SCID): Screened by measuring T-cell receptor excision circles (TRECs). * Spinal Muscular Atrophy (SMA): Screened by DNA analysis for SMN1 gene deletion. * Pompe Disease (Glycogen Storage Disease Type II): Screened by measuring alpha-glucosidase (GAA) enzyme activity. * Mucopolysaccharidosis Type I (MPS I): Screened by measuring alpha-L-iduronidase (IDUA) enzyme activity. This highly extensive panel provides a robust and comprehensive screening for a very wide range of treatable conditions, allowing for early detection and intervention before symptoms develop, which is crucial for preventing severe intellectual disability, developmental delays, organ damage, or even death.

Dried Blood Spot (DBS) / Whole Blood (WB) in EDTA Vacutainer
(The primary sample type for TMS and many of the additional conditions is Dried Blood Spot (DBS), collected via a heel prick on a special filter paper card. Whole Blood (WB) in EDTA is often specifically required for certain molecular or specialized biochemical assays within the "11 conditions" group, such as hemoglobinopathy screening or certain enzyme activity assays, and may also be used as a backup/confirmatory sample.)

Accurate timing and proper sample collection are absolutely critical for the reliability of this extensive newborn screening panel.
* Optimal Timing: The blood samples (Dried Blood Spot - DBS and/or Whole Blood - WB in EDTA) should ideally be collected between 24 to 72 hours (1-3 days) of the baby's life. * Adequate Milk Feeding: It is crucial that the baby has received at least 24 hours of adequate milk feeding (breast milk or formula) prior to blood sample collection. This is vital for activating metabolic pathways and allowing the accumulation of metabolites, which is necessary for accurate detection by TMS and other assays, thereby reducing the chance of false-negative results. * Heel Prick Collection (DBS): A few drops of blood are collected via a gentle heel prick onto a special filter paper card (Guthrie card). It is essential that the designated circles on the card are completely saturated with blood and that the blood soaks through to the back of the card. * Venipuncture (WB EDTA): For the whole blood (EDTA) sample (often required for DNA-based tests like SMA, or certain enzyme/hemoglobin analyses), standard venipuncture techniques should be used to collect the necessary volume. * No Fasting Required: Newborns should not be fasted for this test. Adequate feeding is essential. * Parental Consent: Informed consent from parents is typically obtained before performing such comprehensive screening. * Accurate Information: Accurate demographic information for the baby, feeding status (breastfed/formula), gestational age, birth weight, any medications taken by the mother during pregnancy or by the baby, and details of any transfusions (if applicable, as transfusions can affect certain screening results) should be precisely recorded on the sample submission form. This information is vital for accurate interpretation of results.